Enjoy complimentary customisation on priority with our Enterprise License!
The Exosome Diagnostics and Therapeutics Market size is forecast to increase by USD 687.63 million, at a CAGR of 23.36% between 2023 and 2028. Market growth is influenced by heightened research into exosome therapeutics, escalating demand for efficient treatments for chronic diseases, and a burgeoning emphasis on early cancer detection. The exploration of exosome therapeutics represents a significant advancement in biomedical research, offering promising avenues for targeted drug delivery and regenerative medicine. Concurrently, there is a pressing need for effective therapies to manage chronic conditions, driving innovation and investment in pharmaceutical developments. Moreover, the rising focus on early cancer detection underscores efforts to improve patient outcomes through timely diagnosis and intervention. These trends collectively drive market expansion by fostering collaboration between biotechnology firms, pharmaceutical companies, and research institutions. As scientific understanding and technological capabilities advance, there is increasing optimism regarding the potential of exosome-based therapies and diagnostic tools to revolutionize medical treatments and patient care, addressing critical healthcare challenges worldwide.
The diagnostic segment is estimated to witness significant growth during the forecast period. Exosomes are important for several physiological and pathological processes, such as immunological responses, cancer, cardiovascular disease, and abnormal pregnancies. In addition, reducing the use of invasive procedures and enhancing medical intervention with better accuracy requires the use of liquid biopsy in clinical practice. Furthermore, for customized and precise diagnosis and therapy, non-invasive liquid biopsy demonstrates substantial benefits.
Get a glance at the market contribution of various segments Download PDF Sample
The diagnostic segment was the largest segment and was valued at USD 84.62 million in 2018. Moreover, tumor-derived exosomes (TDEs) are crucial for the development of metastatic niches, immune evasion, and tumor growth, suggesting that TDEs may be extremely useful in determining cancer diagnosis and prognosis and the course of treatment for cancer. For example, the early detection of circulating exoDNA KRAS mutations is common in pancreatic cancer. In addition, given that patients with pancreatic ductal carcinoma (PDAC) and colorectal cancer (CRC) have greater levels of GPC1+ circulating exosomes relative to healthy controls, this could be used as a technique for the early detection of cancers in the digestive tract. Hence, such factors are fuelling the growth of this segment which in turn drives the market growth during the forecast period.
For more insights about the market share of various regions Download PDF Sample now!
North America is estimated to contribute 40% to the growth of the global market during the forecast period. Technavio’s analysts have elaborately explained the regional trends and drivers that will shape the market during the forecast period. There has been an increase in the prevalence of chronic and infectious diseases across North America. In addition, the growing demand for research activities to develop new drugs has increased the demand for exosome research products, which, in turn, is boosting the growth of the market in North America. Furthermore, factors such as the increasing number of cancer cases, the growing adoption of technologically advanced biopsy tests, the growing older population, high expenditure on the screening of various types of cancers, and the increasing number of biotechnology and pharmaceutical companies that push the development of new cancer treatment are driving the market growth in North America during the forecast period.
Companies are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market. The report also includes detailed analyses of the competitive landscape of the market and information about 20 market companies, including:
Aethlon Medical Inc: The company offers Aethlon Hemopurifier which is a first-in-class technology designed for the rapid depletion of cancer-promoting exosomes and circulating viruses.
Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.
The market is rapidly advancing with technology advancements enabling breakthroughs in molecular diagnosis and drug development. Exosomes, enriched with biomolecules such as proteins, metabolites, and nucleic acids including short interfering ribonucleic (siRNA) and antisense oligonucleotides, hold promise in understanding immune responses, viral pathogenicity, and diseases like cancer, neurodegeneration, and cardiovascular dysfunction. They play crucial roles in immune modulation and potentially treating chronic diseases, autoimmune diseases, and infectious conditions. Innovations like the ExoDx Prostate test kit are transforming molecular diagnostics in conditions like prostate cancer. The market's growth is bolstered by scientific research collaborations with institutions like the University of Pittsburgh and funding from the National Institute of Health, emphasizing consumer trust through clean labeling and synthetic ingredients. As demand grows in nutraceuticals and personal care, exosome-based therapies offer novel avenues in health and wellness solutions.
The rising research on exosome therapeutics is a primary driver. Exosomes in cardiovascular diseases (CVDs) have become a prominent research field with promising value and potential. In addition, Shanghai Jiao Tong University and Nanjing Medical University are primary research institutions for exosome therapy in CVDs. Furthermore, many research and academic institutes are working on the development of treatment methods using exosomes.
For example, Beni-Suef University in Egypt is working on the effect of microvesicles and exosome therapy on beta-cell mass in type I diabetes. Fujian Medical University in China is working on MSC-derived exosomes for multiple organ dysfunction. In addition, there are several articles and research reports related to exosome treatment for rare diseases, which has brought attention toward exosome therapy.
A key trend shaping the market growth is the advanced technology in exosome collection. Exosome studies with a combination of immunoaffinity and microfluidic system approaches for more effective exosome collection are among the new technologies employed for exosome isolation. In addition, it aids in manipulating small amounts of fluids, utilizing microchannels through dimensions of tens to hundreds of micrometers.
Moreover, owing to the significant benefits of microfluidic technology, microfluidic devices deliver unique functionality, which has not earlier been possible utilizing traditional methods. In addition, another technology used in exosome tracking cancer is nanoparticle tracking analysis (NTA). Furthermore, it helps to determine the concentration and size distribution of particles.
Issues associated with the broader use of exosome diagnostics and therapeutics are one of the key challenges hindering market growth. Developing a fast and precise method of exosome isolation is one of the most crucial tasks in the current field of research. In addition, the lack of major standardized techniques for the isolation and purification of exosomes is the major drawback of the exosome diagnostics process. Furthermore, the conventional methods of isolation require multi-step ultracentrifugation.
Moreover, this method is very lengthy and often ends up with the contamination of exosomes with other types of extracellular vesicles. In addition, finding optimal conditions for the production of exosomes by a specific cell type is a major challenge, as it is always a compromise between optimal conditions for growth and those for the production and isolation of exosomes. Hence, such factors are hindering the market growth during the forecast period.
The market report includes the adoption lifecycle of the market, covering from the innovator’s stage to the laggard’s stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their growth strategies.
Market Customer Landscape
The market report provides comprehensive market growth by revenue at global, regional & country levels and provides a market growth analysis of the latest market trends and analysis and growth opportunities from 2024 to 2028.
The market is poised for significant growth, driven by advancements in diagnostic procedures and therapeutic applications targeting conditions such as cancer progression, Alzheimer's disease, Parkinson's disease, and more. Exosomes, enriched in chemotherapeutic agents and immune modulators, play a pivotal role in immune responses and combating chronic disease, autoimmune disorders, and infectious diseases. They are crucial in screening for cancer through exosome isolation kits and extraction procedures that analyze body fluids for biomarkers. Challenges include lack of awareness and stringent regulations, yet collaborations with government associations and the VA Healthcare system enhance adoption. As CXOs focus on life science research in LAMEA regions, the market benefits from increased demand among the geriatric population for personalized therapies, cementing exosomes' role in next-generation healthcare solutions. General services encompassing isolation instruments for screening cancer are crucial across a spectrum of health challenges from pregnancy to autoimmune disease and chronic heart failure, breast cancer, liver cancer, and lung cancer, alongside infectious and central nervous system diseases.
Market Scope |
|
Report Coverage |
Details |
Page number |
164 |
Base year |
2023 |
Historic period |
2018-2022 |
Forecast period |
2024-2028 |
Growth momentum & CAGR |
Accelerate at a CAGR of 23.36% |
Market Growth 2024-2028 |
USD 687.63 million |
Market structure |
Fragmented |
YoY growth 2023-2024(%) |
21.73 |
Regional analysis |
North America, Europe, Asia, and Rest of World (ROW) |
Performing market contribution |
North America at 40% |
Key countries |
US, Germany, UK, China, and Japan |
Competitive landscape |
Leading Vendors, Market Positioning of Vendors, Competitive Strategies, and Industry Risks |
Key companies profiled |
Aethlon Medical Inc., Bio Techne Corp., BioCat GmbH, BioVision Inc., Capricor Therapeutics Inc., Cell Guidance Systems Ltd., Clara Biotech Inc., Evox Therapeutics Ltd., Hologic Inc., JSR Life Sciences LLC, Lonza Group Ltd., Merck KGaA, Miltenyi Biotec B.V. and Co. KG, Nanosomix Inc., NX PharmaGen Inc., QIAGEN NV, ReNeuron Group plc, Sarepta Therapeutics Inc, System Biosciences LLC, and Thermo Fisher Scientific Inc. |
Market dynamics |
Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, and Market condition analysis for the forecast period. |
Customization purview |
If our market forecasting report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
Download Sample PDF at your Fingertips
We can help! Our analysts can customize this market research report to meet your requirements. Get in touch
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation by Application
7 Market Segmentation by End-user
8 Customer Landscape
9 Geographic Landscape
10 Drivers, Challenges, and Trends
11 Vendor Landscape
12 Vendor Analysis
13 Appendix
Get lifetime access to our
Technavio Insights
Quick Report Overview:
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.